Novo Nordisk AS NOVO B Financial and Strategic SWOT Analysis Review [Updated: 15022017] Prices from USD $125

07:02 EST 5 Mar 2017 | BioPortfolio Reports

Novo Nordisk AS NOVO B Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Novo Nordisk A/S Novo Nordisk, a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company's product portfolio includes newgeneration insulins, modern insulins, human insulins, oral antidiabetic agents, diabetes devices and others. Novo Nordisk also offers biopharmaceuticals for treating haemostasis, human growth hormone products and hormone replacement therapy. With subsidiaries in Europe, North America, Asia, Latin America and Australia, it markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Novo Nordisk AS Key Recent Developments

Feb 02, 2017: Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016
Jan 11, 2017: Bernstein Litowitz Berger Grossmann LLP Announces Securities Class Action Suit Filed Against Novo Nordisk A/S and Certain of its Senior Executives
Dec 20, 2016: Fluor to Design and Build $2 Billion Diabetes API Manufacturing Facility for Novo Nordisk in North Carolina
Nov 30, 2016: Ablynx Achieves First Milestone As Part Of Collaboration With Novo Nordisk
Nov 14, 2016: Novo Nordisk expands programme to reach 20,000 children with diabetes in developing countries

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Novo Nordisk AS NOVO B Financial and Strategic SWOT Analysis Review [Updated: 15022017] Prices from USD $125


More From BioPortfolio on "Novo Nordisk AS NOVO B Financial and Strategic SWOT Analysis Review [Updated: 15022017] Prices from USD $125"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...